JPWO2020154520A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020154520A5
JPWO2020154520A5 JP2021543315A JP2021543315A JPWO2020154520A5 JP WO2020154520 A5 JPWO2020154520 A5 JP WO2020154520A5 JP 2021543315 A JP2021543315 A JP 2021543315A JP 2021543315 A JP2021543315 A JP 2021543315A JP WO2020154520 A5 JPWO2020154520 A5 JP WO2020154520A5
Authority
JP
Japan
Prior art keywords
epilepsy
composition
pde4
syndrome
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518292A5 (https=
JP2022518292A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014819 external-priority patent/WO2020154520A1/en
Publication of JP2022518292A publication Critical patent/JP2022518292A/ja
Publication of JP2022518292A5 publication Critical patent/JP2022518292A5/ja
Publication of JPWO2020154520A5 publication Critical patent/JPWO2020154520A5/ja
Priority to JP2025009888A priority Critical patent/JP2025081323A/ja
Pending legal-status Critical Current

Links

JP2021543315A 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 Pending JP2022518292A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009888A JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796002P 2019-01-23 2019-01-23
US62/796,002 2019-01-23
PCT/US2020/014819 WO2020154520A1 (en) 2019-01-23 2020-01-23 Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009888A Division JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Publications (3)

Publication Number Publication Date
JP2022518292A JP2022518292A (ja) 2022-03-14
JP2022518292A5 JP2022518292A5 (https=) 2023-02-01
JPWO2020154520A5 true JPWO2020154520A5 (https=) 2023-02-01

Family

ID=71735544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543315A Pending JP2022518292A (ja) 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Country Status (6)

Country Link
US (1) US20220098257A1 (https=)
EP (1) EP3914701B1 (https=)
JP (2) JP2022518292A (https=)
CN (1) CN113490739A (https=)
CA (1) CA3127357A1 (https=)
WO (1) WO2020154520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911603D0 (en) * 2019-08-14 2019-09-25 Healx Ltd Treatment
EP4001923B1 (en) 2020-11-23 2024-06-05 Roche Diagnostics GmbH Laboratory sample distribution system and laboratory automation system
EP4249607A1 (en) * 2022-03-21 2023-09-27 Warszawski Uniwersytet Medyczny Panel of markers for prediction of epilepsy recurrence in patients with tuberous sclerosis and the uses thereof
CN121022847B (zh) * 2025-10-31 2026-02-06 温州医科大学附属眼视光医院 一种敲除斑马鱼pde6a的sgRNA及其在视觉疾病中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4999255B2 (ja) * 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド オリゴヌクレオチド含有薬理学的組成物およびその使用
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
ZA200704251B (en) * 2004-10-28 2008-11-26 Celgene Corp Methods and compositions using PDE4 modulators for treatment and management of central nervous injury
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
EP2037924A2 (en) * 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
EP2334180A4 (en) * 2008-09-15 2013-07-03 Univ California RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
CA2817290A1 (en) * 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
US8865723B2 (en) * 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
EP3766885B1 (en) * 2015-06-17 2022-05-25 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
SG11201806383TA (en) * 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Similar Documents

Publication Publication Date Title
Fimognari Role of oxidative RNA damage in chronic‐degenerative diseases
Esser-Nobis et al. Comparative analysis of African and Asian lineage-derived Zika virus strains reveals differences in activation of and sensitivity to antiviral innate immunity
Dawes et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model
Gomme et al. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression
Rodier et al. Mitotic arrest in the developing CNS after prenatal exposure to methylmercury.
Wang et al. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system
Tiwari et al. MicroRNA‐induced silencing in epilepsy: opportunities and challenges for clinical application
Yang et al. Long noncoding RNA AW112010 promotes the differentiation of inflammatory T cells by suppressing IL-10 expression through histone demethylation
Tran et al. Targeting the r (CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides
Martinez Free-living amebas: infection of the central nervous system.
Li et al. Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the Central Nervous System (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues
UA125963C2 (uk) Олігонуклеотид для індукції батьківської експресії ube3a
JPWO2020154520A5 (https=)
JP2006523139A5 (https=)
JP2018528968A5 (https=)
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
FI2906696T4 (fi) Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
Zhao et al. Analysis of expression profiles of long noncoding RNAs and mRNAs in brains of mice infected by rabies virus by RNA sequencing
RU2010138558A (ru) Новые соединения миphk для ингибирования rtp801
Tapescu et al. The RNA helicase DDX39A binds a conserved structure in chikungunya virus RNA to control infection
Jiang et al. Degradation of microRNA miR-466d-3p by Japanese encephalitis virus NS3 facilitates viral replication and interleukin-1β expression
Ghaemmaghami Biology and genetics of PrP prion strains
Sánchez-Carvajal et al. Time series transcriptomic analysis of bronchoalveolar lavage cells from piglets infected with virulent or low-virulent porcine reproductive and respiratory syndrome virus 1
ATE418992T1 (de) Verwendung von tgf-beta2 antisense oligonukleotiden
Irani et al. Neuroprotective interventions targeting detrimental host immune responses protect mice from fatal alphavirus encephalitis